Immunization with the Yersiniabactin Receptor, FyuA, Protects against Pyelonephritis in a Murine Model of Urinary Tract Infection
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Urinary tract infections (UTI) are common and represent a substantial economic and public health burden. Roughly 80% of these infections are caused by a heterogeneous group of uropathogenic Escherichia coli (UPEC) strains. Antibiotics are standard therapy for UTI, but a rise in antibiotic resistance has complicated treatment, making the development of a UTI vaccine more urgent. Iron receptors are a promising new class of vaccine targets for UTI, as UPEC require iron to colonize the iron-limited host urinary tract and genes encoding iron acquisition systems are highly expressed during infection. Previously, three of six UPEC siderophore and heme receptors were identified as vaccine candidates by intranasal immunization in a murine model of ascending UTI. To complete the assessment of iron receptors as vaccine candidates, an additional six UPEC iron receptors were evaluated. Of the six vaccine candidates tested in this study (FyuA, FitA, IroN, the gene product of the CFT073 locus c0294 , and two truncated derivatives of ChuA), only FyuA provided significant protection ( P = 0.0018) against UPEC colonization. Intranasal immunization induced a robust and long-lived humoral immune response. In addition, the levels of FyuA-specific serum IgG correlated with bacterial loads in the kidneys [Spearman's rank correlation coefficient ρ(14) = −0.72, P = 0.0018], providing a surrogate of protection. FyuA is the fourth UPEC iron receptor to be identified from our screens, in addition to IutA, Hma, and IreA, which were previously demonstrated to elicit protection against UPEC challenge. Together, these iron receptor antigens will facilitate the development of a broadly protective, multivalent UTI vaccine to effectively target diverse strains of UPEC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038 · cited 1×
“For example, the resistance rate of communityacquired UTI isolates to the first-line antibiotic trimethoprimsulfamethoxazole (TMP-SMX) currently exceeds 20% in most areas (11).”
BackgroundCorrelates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745 · cited 1×
“Almost all current vaccines block infection by inducing pathogen-specific antibodies in the serum or mucosa, and if a serological correlate of protection can be identified from a humoral immune response, it can provide a valuable tool to evaluate vaccine efficacy and design (43).”
BackgroundMoriel, D. G., Bertoldi, I., Spagnuolo, A., Marchi, S., Rosini, R., Nesta, B., Pastorello, I., Corea, V. A. M., Torricelli, G., Cartocci, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915077107 · Cited by 261
Garcia, E. C., Brumbaugh, A. R., & Mobley, H. L. T. (2011) · Infection and Immunity · doi:10.1128/iai.01222-10 · Cited by 256 · cited 1×
“Epidemiological studies and gene expression data indicate that fyuA is highly expressed during UTI in women (48), is prevalent among UPEC strains, being carried on the high-pathogenicity island (49, 50), and is an important fitness factor during experimental UTI (51).”
BackgroundMucosal Immunization with Iron Receptor Antigens Protects against Urinary Tract Infection
Alteri, C. J., Hagan, E. C., Sivick, K. E., Smith, S. N., & Mobley, H. L. T. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000586 · Cited by 201
Self-citation
Cited by
Urinary tract infections: epidemiology, mechanisms of infection and treatment options
Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3432 · Cited by 4,213
Urinary Tract Infection: Pathogenesis and Outlook
McLellan, L. K., & Hunstad, D. A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.09.003 · Cited by 382
Porcheron, G., Garénaux, A., Proulx, J., Sabri, M., & Dozois, C. M. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00090 · Cited by 366
Nonantibiotic prevention and management of recurrent urinary tract infection
Sihra, N., Goodman, A., Zakri, R., Sahai, A., & Malde, S. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0106-x · Cited by 307
Zhou, Y., Zhou, Z., Zheng, L., Gong, Z., Li, Y., Jin, Y., Huang, Y., & Chi, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310537 · Cited by 305
Metadata
- Authors
- Brumbaugh, A. R., Smith, S. N., & Mobley, H. L. T.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 2013-09
- Volume
- 81
- Issue
- 9
- Pages
- 3309-3316
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W2059801322
- Cited by
- 124
- References
- 6
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunization with the Yersiniabactin Receptor, FyuA, Protects against Pyelonephritis in a Murine Model of Urinary Tract Infection. https://app.cochat.ai/papers/10.1128/iai.00470-13
- The paper
- Brumbaugh, A. R., Smith, S. N., & Mobley, H. L. T. (2013). Immunization with the Yersiniabactin Receptor, FyuA, Protects against Pyelonephritis in a Murine Model of Urinary Tract Infection. Infection and Immunity. https://doi.org/10.1128/iai.00470-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.